323 related articles for article (PubMed ID: 24037862)
1. Advances in androgen receptor targeted therapy for prostate cancer.
Ahmed A; Ali S; Sarkar FH
J Cell Physiol; 2014 Mar; 229(3):271-6. PubMed ID: 24037862
[TBL] [Abstract][Full Text] [Related]
2. Manipulation of androgens and alterations in the androgen receptor axis in prostate cancer.
Nguyen MM; Wang Z
Minerva Urol Nefrol; 2008 Mar; 60(1):15-29. PubMed ID: 18427432
[TBL] [Abstract][Full Text] [Related]
3. Targeting androgen receptor versus targeting androgens to suppress castration resistant prostate cancer.
Guo C; Yeh S; Niu Y; Li G; Zheng J; Li L; Chang C
Cancer Lett; 2017 Jul; 397():133-143. PubMed ID: 28323036
[TBL] [Abstract][Full Text] [Related]
4. Targeted androgen pathway suppression in localized prostate cancer: a pilot study.
Mostaghel EA; Nelson PS; Lange P; Lin DW; Taplin ME; Balk S; Ellis W; Kantoff P; Marck B; Tamae D; Matsumoto AM; True LD; Vessella R; Penning T; Hunter Merrill R; Gulati R; Montgomery B
J Clin Oncol; 2014 Jan; 32(3):229-37. PubMed ID: 24323034
[TBL] [Abstract][Full Text] [Related]
5. Androgen annihilation as a new therapeutic paradigm in advanced prostate cancer.
Rove KO; Crawford ED
Curr Opin Urol; 2013 May; 23(3):208-13. PubMed ID: 23492838
[TBL] [Abstract][Full Text] [Related]
6. Lessons from in-vivo models of castration-resistant prostate cancer.
Lin D; Gout PW; Wang Y
Curr Opin Urol; 2013 May; 23(3):214-9. PubMed ID: 23385975
[TBL] [Abstract][Full Text] [Related]
7. Key targets of hormonal treatment of prostate cancer. Part 1: the androgen receptor and steroidogenic pathways.
Vis AN; Schröder FH
BJU Int; 2009 Aug; 104(4):438-48. PubMed ID: 19558559
[TBL] [Abstract][Full Text] [Related]
8. The androgen/androgen receptor axis in prostate cancer.
Bluemn EG; Nelson PS
Curr Opin Oncol; 2012 May; 24(3):251-7. PubMed ID: 22327838
[TBL] [Abstract][Full Text] [Related]
9. Investigational therapies targeting the androgen signaling axis and the androgen receptor and in prostate cancer - recent developments and future directions.
Isaacsson Velho P; Carducci MA
Expert Opin Investig Drugs; 2018 Oct; 27(10):811-822. PubMed ID: 30118330
[TBL] [Abstract][Full Text] [Related]
10. Modulation of androgen receptor signaling in hormonal therapy-resistant prostate cancer cell lines.
Marques RB; Dits NF; Erkens-Schulze S; van Ijcken WF; van Weerden WM; Jenster G
PLoS One; 2011; 6(8):e23144. PubMed ID: 21829708
[TBL] [Abstract][Full Text] [Related]
11. New agents and strategies for the hormonal treatment of castration-resistant prostate cancer.
Sharifi N
Expert Opin Investig Drugs; 2010 Jul; 19(7):837-46. PubMed ID: 20524793
[TBL] [Abstract][Full Text] [Related]
12. Androgen receptor targeting drugs in castration-resistant prostate cancer and mechanisms of resistance.
Crona DJ; Milowsky MI; Whang YE
Clin Pharmacol Ther; 2015 Dec; 98(6):582-9. PubMed ID: 26331358
[TBL] [Abstract][Full Text] [Related]
13. Molecular mechanisms underlying resistance to androgen deprivation therapy in prostate cancer.
Wadosky KM; Koochekpour S
Oncotarget; 2016 Sep; 7(39):64447-64470. PubMed ID: 27487144
[TBL] [Abstract][Full Text] [Related]
14. Androgen receptor and antiandrogen therapy in male breast cancer.
Di Lauro L; Barba M; Pizzuti L; Vici P; Sergi D; Di Benedetto A; Mottolese M; Speirs V; Santini D; De Maria R; Maugeri-Saccà M
Cancer Lett; 2015 Nov; 368(1):20-25. PubMed ID: 26276719
[TBL] [Abstract][Full Text] [Related]
15. Androgens and esophageal cancer: What do we know?
Sukocheva OA; Li B; Due SL; Hussey DJ; Watson DI
World J Gastroenterol; 2015 May; 21(20):6146-56. PubMed ID: 26034350
[TBL] [Abstract][Full Text] [Related]
16. A phase II study of mifepristone (RU-486) in castration-resistant prostate cancer, with a correlative assessment of androgen-related hormones.
Taplin ME; Manola J; Oh WK; Kantoff PW; Bubley GJ; Smith M; Barb D; Mantzoros C; Gelmann EP; Balk SP
BJU Int; 2008 May; 101(9):1084-9. PubMed ID: 18399827
[TBL] [Abstract][Full Text] [Related]
17. Antiandrogenic effects of novel androgen synthesis inhibitors on hormone-dependent prostate cancer.
Long BJ; Grigoryev DN; Nnane IP; Liu Y; Ling YZ; Brodie AM
Cancer Res; 2000 Dec; 60(23):6630-40. PubMed ID: 11118046
[TBL] [Abstract][Full Text] [Related]
18. Enzalutamide for the treatment of castration-resistant prostate cancer.
Ha YS; Goodin S; DiPaola RS; Kim IY
Drugs Today (Barc); 2013 Jan; 49(1):7-13. PubMed ID: 23362491
[TBL] [Abstract][Full Text] [Related]
19. The complex role of AR signaling after cytotoxic insult: implications for cell-cycle-based chemotherapeutics.
Comstock CE; Knudsen KE
Cell Cycle; 2007 Jun; 6(11):1307-13. PubMed ID: 17568191
[TBL] [Abstract][Full Text] [Related]
20. Rational design of novel antiandrogens for neutralizing androgen receptor function in hormone refractory prostate cancer.
Singh P; Hallur G; Anchoori RK; Bakare O; Kageyama Y; Khan SR; Isaacs JT
Prostate; 2008 Oct; 68(14):1570-81. PubMed ID: 18668523
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
